Evidence map›Paper›PMID 30953507›Full record

ArticleBMC systems biology2019

Anti-TNF- αtreatment-related pathways and biomarkers revealed by transcriptome analysis in Chinese psoriasis patients.

Lunfei Liu, Wenting Liu, Yuxin Zheng, Jisu Chen, Jiong Zhou, Huatuo Dai, Suiqing Cai, Jianjun Liu, Min Zheng, Yunqing Ren

Open access · diamondAbstract read
In one paragraph

Article in BMC systems biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Lunfei LiuDepartment of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wenting LiuSchool of Public Health and Management, Hubei University of Medicine, Shiyan, Hubei, China.
Yuxin ZhengSecond Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Jisu ChenDepartment of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jiong ZhouDepartment of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Huatuo DaiDepartment of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Suiqing CaiDepartment of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jianjun LiuHuman Genetics, Genome Institute of Singapore, Singapore, Singapore.
Min ZhengDepartment of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yunqing RenDepartment of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. yqren@zju.edu.cn.
Second Affiliated Hospital of Zhejiang University · CNGenome Institute of Singapore · SGZhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-tumor necrosis factor alpha (TNF- α) therapy has made a significant impact on treating psoriasis. Despite these agents being designed to block TNF- α activity, their mechanism of action in the remission of psoriasis is still not fully understood at the molecular level.

resultsTo better understand the molecular mechanisms of Anti-TNF- α therapy, we analysed the global gene expression profile (using mRNA microarray) in peripheral blood mononuclear cells (PBMCs) that were collected from 6 psoriasis patients before and 12 weeks after the treatment of etanercept. First, we identified 176 differentially expressed genes (DEGs) before and after treatment by using paired t-test. Then, we constructed the gene co-expression modules by weighted correlation network analysis (WGCNA), and 22 co-expression modules were found to be significantly correlated with treatment response. Of these 176 DEGs, 79 DEGs (M_DEGs) were the members of these 22 co-expression modules. Of the 287 GO functional processes and pathways that were enriched for these 79 M_DEGs, we identified 30 pathways whose overall gene expression activities were significantly correlated with treatment response. Of the original 176 DEGs, 19 (GO_DEGs) were found to be the members of these 30 pathways, whose expression profiles showed clear discrimination before and after treatment. As expected, of the biological processes and functionalities implicated by these 30 treatment response-related pathways, the inflammation and immune response was the top pathway in response to etanercept treatment, and some known TNF- α related pathways, such as molting cycle process, hair cycle process, skin epidermis development, regulation of hair follicle development, were implicated. Furthermore, additional novel pathways were also suggested, such as heparan sulfate proteoglycan metabolic process, vascular endothelial growth factor production, whose transcriptional regulation may mediate the response to etanercept treatment.

conclusionThrough global gene expression analysis in PBMC of psoriasis patient and subsequent co-expression module based pathway analyses, we have identified a group of functionally coherent and differentially expressed genes (DEGs) and related pathways, which has not only provided new biological insight about the molecular mechanism of anti-TNF- α treatment, but also identified several genes whose expression profiles can be used as potential biomarkers for anti-TNF- α treatment response in psoriasis.

Indexed as

Gene Expression ProfilingAdultBiomarkersChinaEtanerceptGene OntologyHumansMaleMiddle AgedPsoriasisTumor Necrosis Factor-alphaYoung AdultBiomarkersEtanerceptTumor Necrosis Factor-alphaAnti-tumor necrosis factor alpha (TNF- α) treatmentEtanerceptPeripheral blood mononuclear cells (PBMCs)Psoriasis

Identifiers

PMID30953507
PMCPMC6449888
OpenAlexW2926968336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.